At least nine companies have clinical-stage HCV compounds with two or more direct-acting antiviral mechanisms of action. New data have shown SVR rates >90% for combinations built around either a nucleotide/side NS5B polymerase inhibitor or a non-nuc NS5B inhibitor. (A) Bristol-Myers Squibb Co. (NYSE:BMY) has a second-generation NS5A inhibitor in "exploratory development,"